Search This Blog

Wednesday, November 18, 2026

Recursion reports FDA alignment on Phase 3 REC-4881 design for familial adenomatous polyposis

 adenoma excisions of at least 10 mm in the primary endpoint

https://finviz.com/stock?t=RXRX&p=d

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.